***Background.*** Recent clinical trials have shown that switching from PI/r or NNRTI to RPV/TDF/FTC is safe and effective in virologically suppressed HIV-infected patients. In this study, we assessed the tolerability, metabolic profile, maintenance of virologic suppression and changes in renal function after switching to RPV/TDF/FTC in a clinical setting.

***Methods.*** Retrospective chart review of HIV-infected individuals on stable ART for at least 6 months and HIV RNA levels \<200 copies/mL whose ART was switched to RPV/TDF/FTC for simplicity, dyslipidemia or ARV intolerance. Wilcoxon signed rank tests and paired t tests were used to test the changes of the lab results and 10-year cardiovascular risk.

***Results.*** 162 out of 175 subjects were analyzed at week 6 ± 4 (n = 140), 24 ± 8 (n = 137) and 48 ± 8 (n = 139). 33% were female; 32% African-American and 57% Hispanic/Latino. Baseline ARV regimen contained NNRTI in 55% and PI/r in 41% of subjects. 18 (11%) of 162 subjects discontinued RPV/TDF/FTC: 3 (2%) due to virologic failure (HIV RNA ≥200 copies/mL) and 6 (4%) grade ≥3 adverse event (2 CNS symptoms, 2 liver toxicity, 1 pancreatitis and 1 acute renal failure). Adverse events occurred in 19 (12%) subjects: 10 reported CNS symptoms, 4 liver toxicity, 2 acute renal failures and 1 each of CV event, pancreatitis and cutaneous reaction. 7 subjects developed virologic failure; 3 subjects continued RPV/TDF/FTC achieving re-suppression.

There was significant improvement (mean ± SD, -0.41 ± 1.54, P = 0.04) in 10-year Framingham Cardiovascular Risk score (%) from baseline (4.57 ± 5.01) to week 24 (4.16 ± 4.71). Mean (SD) changes from baseline in creatinine were 0.03 mg/dL (0.15) at week 24 (P = 0.02).

###### 

Median (Interquartile Range) changes from baseline in fasting lipid parameters (mg/dL)

  Visit               Baseline          Week 24           Change from Baseline   *P* (Wilcoxon signed rank test)
  ------------------- ----------------- ----------------- ---------------------- ---------------------------------
  Total Cholesterol   183 (163 , 212)   161 (145 , 183)   -20 (-38 , -1)         \<0.0001
  LDL-Cholesterol     106 (88 , 129)    99 (82 , 119)     -8 (-22 , 9)           \<0.0001
  HDL-Cholesterol     43 (35 , 54)      39 (33 , 47)      -4 (-10 , 2)           \<0.0001
  Triglycerides       147 (106 , 247)   112 (78 , 161)    -34 (-97 , -6)         0.006

***Conclusion.*** Switching to RPV/TDF/FTC resulted in significant improvement in lipid profile leading to a decrease in 10-year Framingham Risk score at week 24. It was well tolerated with low rates of discontinuation due to adverse events.
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